Use of glyburide for the treatment of gestational diabetes: the San Antonio experience

Objective: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment.Methods: Women with GDM treated wi...

Full description

Saved in:
Bibliographic Details
Published in:The journal of maternal-fetal & neonatal medicine 2004, Vol.15 (1), p.51-55
Main Authors: Conway, D. L., Gonzales, O., Skiver, D.
Format: Article
Language:English
Subjects:
Adult
Blood Glucose - drug effects
Blood Glucose - metabolism
Diabetes
Diabetes, Gestational - blood
Diabetes, Gestational - drug therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gestation
Glyburide
Glyburide - administration & dosage
Glyburide - therapeutic use
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Pregnancy
Randomized Controlled Trials as Topic
Retrospective Studies
Texas
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment.Methods: Women with GDM treated with glyburide were studied. They were divided into two groups: those who achieved adequate glycemic control with glyburide, and those who did not. The groups were compared in terms of baseline characteristics, including diabetes risk factors and glucose testing values. Receiver operating characteristics (ROC) curves were generated to identify thresholds for fasting plasma glucose and body mass index (BMI) that would predict glyburide failure.Results: Seventy-five women were analyzed: 63 (84%) were successfully treated with glyburide, and 12 (16%) were not. Baseline characteristics were similar between the groups, except that failures had higher 3-h glucose tolerance test (GTT) values at all time points. ROC curves for fasting plasma glucose, pre-pregnancy BMI and BMI at diagnosis revealed no cut-off points for predicting failure of glyburide therapy. However, when fasting plasma glucose value on the GTT was ≥110 mg dl, 24% of women failed to respond to glyburide, compared to 12% at
ISSN:1476-7058
1476-4954
DOI:10.1080/14767050310001650725